Financhill
Sell
47

A Quote, Financials, Valuation and Earnings

Last price:
$135.95
Seasonality move :
5.89%
Day range:
$134.15 - $136.10
52-week range:
$124.16 - $155.35
Dividend yield:
0.69%
P/E ratio:
30.79x
P/S ratio:
6.08x
P/B ratio:
6.59x
Volume:
369.2K
Avg. volume:
1.9M
1-year change:
-2.49%
Market cap:
$38.9B
Revenue:
$6.5B
EPS (TTM):
$4.42

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
A
Agilent Technologies
$1.7B $1.41 0.68% 7.74% $149.52
AZTA
Azenta
$169.8M $0.11 -3.09% 86.12% --
BIO
Bio-Rad Laboratories
$628.6M $1.18 -0.09% -76.23% --
BNGO
Bionano Genomics
$7.8M -$0.16 -41.24% -92.86% --
BRKR
Bruker
$866.1M $0.60 12.69% -47.58% $74.01
HBIO
Harvard Bioscience
$23.7M $0.02 -14.22% 150% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
A
Agilent Technologies
$136.10 $149.52 $38.9B 30.79x $0.24 0.69% 6.08x
AZTA
Azenta
$50.25 -- $2.3B -- $0.00 0% 4.08x
BIO
Bio-Rad Laboratories
$330.53 -- $9.3B -- $0.00 0% 3.64x
BNGO
Bionano Genomics
$0.20 -- $20.6M -- $0.00 0% 0.28x
BRKR
Bruker
$58.25 $74.01 $8.8B 28.00x $0.05 0.34% 2.66x
HBIO
Harvard Bioscience
$2.08 -- $90.7M -- $0.00 0% 0.92x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
A
Agilent Technologies
36.5% 1.308 9.12% 1.40x
AZTA
Azenta
-- 2.021 -- 3.10x
BIO
Bio-Rad Laboratories
13.83% 1.191 12.83% 4.19x
BNGO
Bionano Genomics
23.43% 3.362 37.24% 0.86x
BRKR
Bruker
55.97% 2.514 21.87% 0.65x
HBIO
Harvard Bioscience
36.69% 0.925 32.27% 0.76x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
A
Agilent Technologies
$916M $408M 14.58% 21.45% 25.46% $388M
AZTA
Azenta
$69.4M -$11M -7.49% -7.49% -6.48% $1.7M
BIO
Bio-Rad Laboratories
$355.9M $64.5M -8.38% -9.62% 134.49% $100M
BNGO
Bionano Genomics
-$8.4M -$22.6M -121.16% -158.95% -727.05% -$13.3M
BRKR
Bruker
$418.8M $78.4M 9.46% 19.61% 7.74% $5.8M
HBIO
Harvard Bioscience
$12.8M -$1.7M -13.35% -20.42% -16.55% -$2M

Agilent Technologies vs. Competitors

  • Which has Higher Returns A or AZTA?

    Azenta has a net margin of 20.64% compared to Agilent Technologies's net margin of -2.93%. Agilent Technologies's return on equity of 21.45% beat Azenta's return on equity of -7.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    A
    Agilent Technologies
    53.85% $1.22 $9.3B
    AZTA
    Azenta
    40.82% -$0.10 $1.8B
  • What do Analysts Say About A or AZTA?

    Agilent Technologies has a consensus price target of $149.52, signalling upside risk potential of 9.86%. On the other hand Azenta has an analysts' consensus of -- which suggests that it could grow by 12.64%. Given that Azenta has higher upside potential than Agilent Technologies, analysts believe Azenta is more attractive than Agilent Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    A
    Agilent Technologies
    6 9 0
    AZTA
    Azenta
    0 0 0
  • Is A or AZTA More Risky?

    Agilent Technologies has a beta of 1.066, which suggesting that the stock is 6.613% more volatile than S&P 500. In comparison Azenta has a beta of 1.493, suggesting its more volatile than the S&P 500 by 49.318%.

  • Which is a Better Dividend Stock A or AZTA?

    Agilent Technologies has a quarterly dividend of $0.24 per share corresponding to a yield of 0.69%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios A or AZTA?

    Agilent Technologies quarterly revenues are $1.7B, which are larger than Azenta quarterly revenues of $170.1M. Agilent Technologies's net income of $351M is higher than Azenta's net income of -$5M. Notably, Agilent Technologies's price-to-earnings ratio is 30.79x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.08x versus 4.08x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    A
    Agilent Technologies
    6.08x 30.79x $1.7B $351M
    AZTA
    Azenta
    4.08x -- $170.1M -$5M
  • Which has Higher Returns A or BIO?

    Bio-Rad Laboratories has a net margin of 20.64% compared to Agilent Technologies's net margin of -339.17%. Agilent Technologies's return on equity of 21.45% beat Bio-Rad Laboratories's return on equity of -9.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    A
    Agilent Technologies
    53.85% $1.22 $9.3B
    BIO
    Bio-Rad Laboratories
    54.78% $23.34 $8.7B
  • What do Analysts Say About A or BIO?

    Agilent Technologies has a consensus price target of $149.52, signalling upside risk potential of 9.86%. On the other hand Bio-Rad Laboratories has an analysts' consensus of -- which suggests that it could grow by 22.33%. Given that Bio-Rad Laboratories has higher upside potential than Agilent Technologies, analysts believe Bio-Rad Laboratories is more attractive than Agilent Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    A
    Agilent Technologies
    6 9 0
    BIO
    Bio-Rad Laboratories
    1 2 0
  • Is A or BIO More Risky?

    Agilent Technologies has a beta of 1.066, which suggesting that the stock is 6.613% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.429%.

  • Which is a Better Dividend Stock A or BIO?

    Agilent Technologies has a quarterly dividend of $0.24 per share corresponding to a yield of 0.69%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios A or BIO?

    Agilent Technologies quarterly revenues are $1.7B, which are larger than Bio-Rad Laboratories quarterly revenues of $649.7M. Agilent Technologies's net income of $351M is lower than Bio-Rad Laboratories's net income of $653.2M. Notably, Agilent Technologies's price-to-earnings ratio is 30.79x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.08x versus 3.64x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    A
    Agilent Technologies
    6.08x 30.79x $1.7B $351M
    BIO
    Bio-Rad Laboratories
    3.64x -- $649.7M $653.2M
  • Which has Higher Returns A or BNGO?

    Bionano Genomics has a net margin of 20.64% compared to Agilent Technologies's net margin of -728.57%. Agilent Technologies's return on equity of 21.45% beat Bionano Genomics's return on equity of -158.95%.

    Company Gross Margin Earnings Per Share Invested Capital
    A
    Agilent Technologies
    53.85% $1.22 $9.3B
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
  • What do Analysts Say About A or BNGO?

    Agilent Technologies has a consensus price target of $149.52, signalling upside risk potential of 9.86%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 394.07%. Given that Bionano Genomics has higher upside potential than Agilent Technologies, analysts believe Bionano Genomics is more attractive than Agilent Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    A
    Agilent Technologies
    6 9 0
    BNGO
    Bionano Genomics
    0 0 0
  • Is A or BNGO More Risky?

    Agilent Technologies has a beta of 1.066, which suggesting that the stock is 6.613% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.944%.

  • Which is a Better Dividend Stock A or BNGO?

    Agilent Technologies has a quarterly dividend of $0.24 per share corresponding to a yield of 0.69%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios A or BNGO?

    Agilent Technologies quarterly revenues are $1.7B, which are larger than Bionano Genomics quarterly revenues of $6.1M. Agilent Technologies's net income of $351M is higher than Bionano Genomics's net income of -$44.2M. Notably, Agilent Technologies's price-to-earnings ratio is 30.79x while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.08x versus 0.28x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    A
    Agilent Technologies
    6.08x 30.79x $1.7B $351M
    BNGO
    Bionano Genomics
    0.28x -- $6.1M -$44.2M
  • Which has Higher Returns A or BRKR?

    Bruker has a net margin of 20.64% compared to Agilent Technologies's net margin of 4.73%. Agilent Technologies's return on equity of 21.45% beat Bruker's return on equity of 19.61%.

    Company Gross Margin Earnings Per Share Invested Capital
    A
    Agilent Technologies
    53.85% $1.22 $9.3B
    BRKR
    Bruker
    48.45% $0.27 $4.1B
  • What do Analysts Say About A or BRKR?

    Agilent Technologies has a consensus price target of $149.52, signalling upside risk potential of 9.86%. On the other hand Bruker has an analysts' consensus of $74.01 which suggests that it could grow by 27.05%. Given that Bruker has higher upside potential than Agilent Technologies, analysts believe Bruker is more attractive than Agilent Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    A
    Agilent Technologies
    6 9 0
    BRKR
    Bruker
    7 5 0
  • Is A or BRKR More Risky?

    Agilent Technologies has a beta of 1.066, which suggesting that the stock is 6.613% more volatile than S&P 500. In comparison Bruker has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.733%.

  • Which is a Better Dividend Stock A or BRKR?

    Agilent Technologies has a quarterly dividend of $0.24 per share corresponding to a yield of 0.69%. Bruker offers a yield of 0.34% to investors and pays a quarterly dividend of $0.05 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios A or BRKR?

    Agilent Technologies quarterly revenues are $1.7B, which are larger than Bruker quarterly revenues of $864.4M. Agilent Technologies's net income of $351M is higher than Bruker's net income of $40.9M. Notably, Agilent Technologies's price-to-earnings ratio is 30.79x while Bruker's PE ratio is 28.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.08x versus 2.66x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    A
    Agilent Technologies
    6.08x 30.79x $1.7B $351M
    BRKR
    Bruker
    2.66x 28.00x $864.4M $40.9M
  • Which has Higher Returns A or HBIO?

    Harvard Bioscience has a net margin of 20.64% compared to Agilent Technologies's net margin of -21.86%. Agilent Technologies's return on equity of 21.45% beat Harvard Bioscience's return on equity of -20.42%.

    Company Gross Margin Earnings Per Share Invested Capital
    A
    Agilent Technologies
    53.85% $1.22 $9.3B
    HBIO
    Harvard Bioscience
    58.1% -$0.11 $103.2M
  • What do Analysts Say About A or HBIO?

    Agilent Technologies has a consensus price target of $149.52, signalling upside risk potential of 9.86%. On the other hand Harvard Bioscience has an analysts' consensus of -- which suggests that it could grow by 200.48%. Given that Harvard Bioscience has higher upside potential than Agilent Technologies, analysts believe Harvard Bioscience is more attractive than Agilent Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    A
    Agilent Technologies
    6 9 0
    HBIO
    Harvard Bioscience
    0 0 0
  • Is A or HBIO More Risky?

    Agilent Technologies has a beta of 1.066, which suggesting that the stock is 6.613% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.272, suggesting its more volatile than the S&P 500 by 27.217%.

  • Which is a Better Dividend Stock A or HBIO?

    Agilent Technologies has a quarterly dividend of $0.24 per share corresponding to a yield of 0.69%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios A or HBIO?

    Agilent Technologies quarterly revenues are $1.7B, which are larger than Harvard Bioscience quarterly revenues of $22M. Agilent Technologies's net income of $351M is higher than Harvard Bioscience's net income of -$4.8M. Notably, Agilent Technologies's price-to-earnings ratio is 30.79x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.08x versus 0.92x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    A
    Agilent Technologies
    6.08x 30.79x $1.7B $351M
    HBIO
    Harvard Bioscience
    0.92x -- $22M -$4.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
87
PSIX alert for Dec 26

Power Solutions International [PSIX] is up 2.51% over the past day.

Buy
65
TSLL alert for Dec 26

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 2.17% over the past day.

Buy
75
SMLR alert for Dec 26

Semler Scientific [SMLR] is down 2.92% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock